ReviewCancer management and research2026
Targeting Oncogenic miRNAs in NSCLC: Therapeutic Strategies and Emerging Approaches.
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths globally, with poor prognosis in advanced stages despite therapeutic advances. MicroRNAs (miRNAs) play a critical role in NSCLC pathogenesis, acting as tumor suppressors or oncogenes (oncomiRs), regulating key pathways involved in cancer progression and drug resistance. This review explores various therapeutic strategies targeting oncogenic miRNAs in NSCLC, with a particular focus on small molecule inhibitors (SMIs). SMIs offer potential advantages over RNA-based therapies, such as better pharmacokinetics and oral bioavailability, though direct evidence for SMIs targeting oncogenic miRNAs in NSCLC remains limited. The review examines current research on SMIs, miRNA mimics, antisense oligonucleotides, and other approaches, while discussing the challenges and opportunities for clinical translation. It concludes that while miRNA-based therapies are promising, substantial research is needed to develop effective and selective small molecule inhibitors for NSCLC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.